Citizens Jmp Boosts Progyny (NASDAQ:PGNY) Price Target to $31.00

Progyny (NASDAQ:PGNY) had its target price boosted by research analysts at Citizens Jmp from $30.00 to $31.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s target price points to a potential upside of 35.64% from the stock’s current price.

A number of other equities research analysts also recently issued reports on PGNY. BTIG Research reduced their price target on shares of Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Truist Financial lowered their price target on shares of Progyny from $34.00 to $28.00 and set a “buy” rating for the company in a report on Monday, March 2nd. JPMorgan Chase & Co. set a $35.00 target price on shares of Progyny in a research report on Wednesday, January 21st. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Finally, Canaccord Genuity Group reduced their target price on shares of Progyny from $26.00 to $19.00 and set a “hold” rating for the company in a research note on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

Progyny Stock Down 3.7%

Shares of NASDAQ:PGNY traded down $0.87 during midday trading on Monday, reaching $22.85. The company’s stock had a trading volume of 425,220 shares, compared to its average volume of 1,518,527. The firm has a market capitalization of $1.79 billion, a PE ratio of 29.73, a P/E/G ratio of 1.37 and a beta of 0.91. The stock has a fifty day moving average of $17.87 and a 200 day moving average of $21.69. Progyny has a twelve month low of $16.10 and a twelve month high of $28.75.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.26 by $0.03. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The company had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.47 million. During the same quarter last year, the business earned $0.17 earnings per share. The firm’s revenue was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Sell-side analysts anticipate that Progyny will post 1.12 earnings per share for the current fiscal year.

Insider Activity at Progyny

In other news, EVP Allison Swartz sold 4,657 shares of the business’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the transaction, the executive vice president directly owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. The trade was a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 7,455 shares of company stock worth $129,515 over the last 90 days. Insiders own 9.90% of the company’s stock.

Institutional Trading of Progyny

Several institutional investors have recently added to or reduced their stakes in PGNY. Wellington Management Group LLP increased its stake in Progyny by 260.9% during the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after purchasing an additional 1,621,688 shares during the last quarter. Fort Washington Investment Advisors Inc. OH lifted its holdings in Progyny by 46.9% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock worth $45,734,000 after purchasing an additional 859,289 shares during the period. Loomis Sayles & Co. L P acquired a new stake in Progyny in the fourth quarter worth about $19,917,000. Barclays PLC lifted its holdings in Progyny by 79.2% in the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock worth $33,904,000 after purchasing an additional 696,447 shares during the period. Finally, Ameriprise Financial Inc. lifted its holdings in Progyny by 37.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after acquiring an additional 545,431 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.